People with extreme, life-threatening allergic reactions might do as well to use a nasal spray as to jab themselves in a ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Q. On my last few trips, I developed severe nasal allergies and runny nose while on the plane. It was uncomfortable and embarrassing. Other travelers may have thought I had a bad cold or something ...

Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance ...

Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data ...

QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 ...

Long-term use of inhalers and nasal sprays, common for respiratory issues, may increase infection risks, a meta-analysis ...

Evoke Pharma surges after QOL Medical announces $11 cash acquisition, a 140% premium, expected to close by the end of 2025.

Some experts believe, with proper precautions—and when other treatments have failed—that ketamine-assisted psychotherapy can ...